# Guidelines for the Use of Serum Tests of Iron Stores

#### 1. Background

Ferritin is the major storage protein for iron. It is present in virtually all cells where it sequesters iron in a soluble form providing accessible reserves for synthesis of iron containing compounds such as hemoglobin. It is present in particularly large amounts in macrophages and hepatocytes for storage and for metabolic purposes in erythroblasts. Although not a transport protein like transferrin, ferritin is present in small concentrations in the plasma which are directly proportional to the body's total iron stores. This relationship makes the serum or plasma assay for ferritin an ideal non invasive test of iron status.

Traditionally serum iron and the total iron binding capacity (TIBC) and the percent saturation, an indirect measurement of transferrin, have been used to determine iron status. A reduced level of serum iron *and* an elevated TIBC are required for a diagnosis of iron deficiency, whereas an increased proportion of saturation is suggestive of iron overload. (1)

### 2. Limitations

Levels of ferritin in the plasma are increased in acute and chronic inflammation as well as in certain malignancies such as Hodgkin's Disease. It is also elevated in hepatic cell damage which may make elevated levels difficult to interpret in hemochromatosis. An individual assay value must be interpreted with respect to any associated clinical conditions.

Plasma iron demonstrates substantial circadian fluctuations and day to day variations of as much as 30%. It can also be increased in inflammation, ineffective erythropoiesis and as a result of oral iron therapy. Transferrin, on the other hand, is reduced in inflammation, malignancies, liver diseases and malnutrition but is increased in pregnancy and as a result of oral contraceptives. These fluctuations in plasma levels unrelated to iron status can render the iron, TIBC and % saturation meaningless in many clinical situations. (2)

# 3. Alternative Tests

#### **Iron Deficiency**

The iron stain of an aspirated bone marrow particle is considered the gold standard for comparison of serum tests. However, on rare occasions it can provide a positive iron reaction although the patient is functionally iron deficient. These misleading stains tend to be associated with chronic inflammatory disease and the use of intravenous iron. Other tests, including free erythrocyte protoporphyrin, red cell ferritin and transferrin receptor have been used but do not demonstrate improved capabilities over the serum ferritin assay. (3)

#### **Iron Overload**

The definitive assay for increased iron stores is the iron content of a liver biopsy which is usually obtained by the percutaneous or transjugular route. Non-invasive methodologies being used by specialist

units include magnetic susceptometry and magnetic resonance imaging (MRI) but these techniques are only used to monitor accurately response to therapy and are not screening tests.

## 4. Indications

#### **Iron Deficiency**

The extremely high prevalence of iron deficiency in menstruating and pregnant females, adolescents and those on diets with poor iron intake along with the high sensitivity and specificity of the serum ferritin makes this the ideal diagnostic test. Levels will be decreased before there is a decrease in the mean red cell volume (MCV) or anemia. It has been suggested that the traditional cut off between deficient and normal be reconsidered (usually between 12 and 20 microgram/L) and that the statistical likelihood of iron deficiency does not decrease until values are > 40 microgram/L for uncomplicated populations and > 70 microgram/L for cases with inflammation or liver disease. (4)

Serum Iron, TIBC and % saturation, despite reduced specificity, will still be useful tests due to the high prevalence of deficiency. However, their value is considerably less in complicated situations and they add very little diagnostic value to the ferritin assay. For these reasons, it is not recommended that these tests be ordered in addition to ferritin in detection of iron deficiency.

A bone marrow aspiration and a stain of the particles for iron may be necessary in some cases.

#### **Iron Overload**

Detection of iron overload is important to recognize due to the toxic effects of excess iron on the liver and heart in particular. Overload may occur due to hereditary hemochromatosis (present in 0.5 percent of North Americans) and in homozygous thalassemic conditions, part of which is due to the transfusional iron excess. (5) Screening for hemochromatosis requires measurement of transferrin saturation. If > 60% saturation in men or > 50% in women, a ferritin assay is the next step. If the ferritin is normal, repeat screening every two years is indicated. However, if ferritin is elevated, then further investigation by liver biopsy is warranted.

Interpretation of these screening tests requires caution. The serum ferritin generally reflects iron stores up to a level of 4,000 microgram/L. However, in a few cases of hemochromatosis the level may be a serious underestimate or even normal for no known reasons. The serum iron will be elevated, TIBC reduced and the % saturation increased in established cases but will provide no guide to the degree of overload. As with the ferritin, on occasions the % saturation will be erroneously normal for no obvious reason and sometimes levels will be affected by other complicating conditions described above.

A comparative study of the clinical usefulness of these tests looked at results from 1053 samples submitted to a reference laboratory from community and hospital patients. Although serum ferritin identified 239 cases of iron deficiency (23%), the serum iron and % saturation only identified 64 cases, all but four of which also had a low serum ferritin level. Physicians may have been ordering these tests for iron overload but only 131 cases had an increased % saturation, although 303 had elevated serum ferritin levels.

# 5. Interpretation

# Tests to detect iron deficiency

Serum ferritin

|                                    | < normal range                                | iron deficiency, high degree of confidence   |  |
|------------------------------------|---|--|--|
|                                    | $< 40 \ \mu g/L$                              | possible iron deficiency, lesser degree of confidence  |  |
|                                    | < 70 µg/L                                     | iron deficiency in patients with inflammation, moderate degree of confidence                                   |  |
| Serum Iron<br>TIBC                 | decreased elevated                            | iron deficiency, moderate degree of confidence   |  |
| TIBC                               | normal  | results are inconclusive   |  |
| Tests to detect iron overload      |   |  |  |
| Serum ferritin                     | increased levels                              | reflect increased body stores  |  |
| Serum iron<br>TIBC<br>% saturation | increased<br>decreased or normal<br>increased | increased stores but changes are not<br>proportional to degree of overload<br>> 60% in males, > 50% in females |  |
|                                    |   |  |  |

### 6. References

Finch CA, Heubers H. Perspectives in Iron Metabolism. N Eng J Med 306, 1520-1528 (1982).

Edwards CQ, Kushner JP. Screening for Hemochromatosis. N Eng J Med 328, 1616-1620 (1993).

Bothwell TH, Charlton RW, Cook JD, Finch CA. *Iron Metabolism in man.* Blackwell Scientific Publications, Oxford (1979).

Guyatt GH, Oxman AD, Ali M *et al.* Laboratory Diagnosis of Iron Deficiency Anemia: An Overview. J Gen Intern Med 7, 145-153 (1992).

Hoffam R, Benz EJ, Shattil SJ, et al. Eds Hematology: Basic principles and practice. Churchill Livingstone Inc. Chap 29, 327-349 (1991).

Wands JR, Rowe JA, Mezey S *et al.* Normal serum ferritin concentrations in precirrhotic hemochromatosis. N Eng J Med 294, 302 (1976).

Sheridan BL, Pearce LC. Serum Tests to Detect Iron Deficiency. Clin Chem, 30, 1271 (1984).

#### 7. Acknowledgements

The **Ontario Association of Medical Laboratories** gratefully acknowledges the contributions of Brian Sheridan, MD, others who participated in the development of this guideline and all those who reviewed this document.

This document was reviewed by the Laboratory Medicine section of the Ontario Medical Association and in its short form by the Internal Medicine, Gastroenterology, Hematology/Oncology and Laboratory Medicine sections of the OMA.

# The Ontario Association of Medical Laboratories

The Ontario Association of Medical Laboratories (OAML) represents the community-based laboratory sector in Ontario.

Its mission is to promote excellence in the provision of laboratory services and, as an essential component of the health care system, to contribute to shaping the future of health care in Ontario.

The OAML encourages the highest level of professional and ethical integrity and technical excellence among laboratory owners, operators and staff in the provision of laboratory services for the benefit of the people of Ontario.

| <b>Guidelines for Clinical Laboratory Practice</b><br>The OAML, through its Quality Assurance and Clinical<br>Laboratory Practice Committee, co-ordinates the | There may be additional educational materials produced,<br>if it is thought that they might be useful, and these are<br>distributed with the guideline. |
|---|---|
| development and dissemination, implementation and   | The comments of end users are essential to the  |
| evaluation of Guidelines for Clinical Laboratory Practice.  | development of guidelines and will encourage adherence.<br>You are strongly encouraged to submit your comments on                                       |
| A proposed Guideline is developed by a working group  | this or on any other OAML Guideline to:   |
| of the Committee with the participation of outside  |   |
| experts. The proposed guideline is then submitted to the  | Chair   |
| Committee as a whole and to a Professional Advisory   | Quality Assurance and Clinical Laboratory Practice  |
| Group who provide an overall review of the document.  | Committee   |
| The comments of the Committee and the Professional  | Ontario Association of Medical Laboratories   |
| Advisory Group are incorporated into a revision of the  | 5160 Yonge Street, Suite 710  |
| guideline and this draft is submitted to laboratory Medical   | North York, Ontario   |
| Directors, professional associations and other  | M2N 6L9   |
| representatives of end users for additional comment. The  |   |
| document is revised in light of these comments and  | Tel: (416) 250-8555   |
| submitted to the OAM L Board of Directors for approval.   | Fax: (416) 250-8464   |
|   | E-mail: oaml@oaml.com   |

| Approved guidelines are distributed to Community-          | Internet: http://www.oaml.com |
|--|-------------------------------|
| based Laboratories and by them to their client physicians. |                               |
|  |                               |

© 1995 OAML CLP001 Issued June, 1995